Instructions to Authors

  1. General

Manuscripts submitted to JPSPP will be reviewed for possible publication on the strict condition that no part of or the whole manuscript has been published previously, or is under consideration for publication in another journal at the same time. Articles sent by any member of the editorial team will be reviewed independently. Manuscripts submitted to JPSPP can be any of the following:

Original research article:

Original research articles must provide scientifically sound experiments and a substantial amount of new information relevant to the scientific community. The method section must contain full experimental details of the research for reproducibility. All experimental data including control experiments should be included. Full experimental article should be structured into introduction, methods, results, discussion and conclusion. Original research should not be more than 6,000 words, including tables and illustrations. However, the word count excludes the title page, abstract, acknowledgements, and references. In case of additional data, these may be presented as supplementary data to be published when the article is accepted for publication. 

Short communication:

Short communication is a concise, independent report presenting a significant contribution to science.  Although not always intended, short communication may project preliminary, but significant results of a research work. This should not be more than 2500 words

Review article:

Journal of Pharmaceutical Sciences and Pharmacy Practice (JPSPP) accepts systematic reviews, meta-analyses that has followed PRISMA guidelines. Authors intending to submit a review article may consider sending an outline to the Editor-in- Chief before preparing their article. The outline must include a detailed abstract using the structure provided under manuscript format (see below), an annotated table of contents and a short Curriculum Vitea (CV) of the lead author justifying mastery of the field of review. Review articles must not be longer than 9000 words. Authors must notify the Editor-in-Chief in case their review would be longer. The organization and subdivision of review articles are at the author’s discretion. Authors should keep in mind that a good review sets the trend and direction of future research on the subject matter being reviewed. Tables, figures and references are to be arranged in the same way as original research articles in the journal. Reviews on topics addressing cutting-edge phenomena in all areas of pharmaceutical sciences are particularly welcomed.

  1. Manuscript format

Manuscript must be written in concise and easily understandable English and submitted electronically. It should be in MS word, double-spaced (except the title which must be single spaced) on A4 (8.5″ x 11″) paper size with 1 inch margins. This typeface (font) should be Times New Roman size 12 except the title which should be size 14.

Manuscript must be structured into the following main sections: Title, Abstract, Keywords, introduction, Materials and Methods, Results, Discussion, Conclusion, Declaration of Conflict of interest, Acknowledgements and References.


The title page must be on a separate page consisting of the title, names and affiliations of the corresponding authors and other authors. Affiliation footnote should be stated in numerical order of first mention indicated in the authors’ names. Phone number and email address of the correspondence author should be provided.

The title should be concise (preferably not more than 18 words) and reflective of the key elements of the research. It should be in sentence case, capitalizing only the first letter of the first word, any other proper nouns and genus (common) names. The title must be devoid of unconventional abbreviations and symbols. It should be followed by the Author’ full names (surname last), indicating affiliations with superscripted numbers and an asterisk, in addition, to the name of the correspondence author.


Abstract must be structured into: Background, Methodology, Results and Conclusions/ Recommendations, and should start on a separate page.  It should not be more than 250 words. Excessive use of abbreviations is discouraged and when used, should be stated in full on first appearance  

Keywords- A maximum of 4-6 keywords are required for indexing purposes, and should be provided beneath the abstract. The keywords should express the precise content of the manuscript.



Introduction, should also provide the contextual and relevant background of the study, with relevant references. It should be devoid of detailed descriptions of experimental procedures (methods), current results and conclusion.

Materials and Methods

All materials used for the current study and their sources should be stated. Detailed experimental procedures should be presented if novel. Other standard or already published procedures should be simply referred to by literature citation. Spectroscopic data for characterization of new compounds should be described in sufficient details. Plants must be identified by experience botanists and specimen deposited in a recognized herbarium with Voucher Specimen Numbers. Experiments involving the use of live animals must include a statement of approval by an ethical committee and certifying that such experiments were performed in accordance with all international guidelines and regulations. For experiments involving humans or tissue samples, a statement that informed consent was obtained from the subject or from the next of kin must be included. Ethical approval for the study must be provided

Results should be clear and concise. Unnecessary duplication of results should be avoided. Results can be presented either as table or figure, and not both. Tables and figures should not be more than three. Tables without grids are preferred. No shading of table cells. Comments on the implication of significance of the result findings should be restricted to the discussion section


This should explore the results and their significance. Care must, however, be taken to avoid repetition of results. Extensive citations and discussion of already published work should be avoided.

The main conclusions of the study should be line with the study objectives . This section should stand alone and not merged with discussions.

Conflict-of-Interest Disclosure

Authors should make a statement describing any financial conflicts of interest or lack thereof.


Authors should acknowledge the funding body including all those who assisted in the work but did not qualify as authors


References should be cited in the text with superscripted Arabic numerals and listed at the end of the text in order of citation, using the following formats:


Reference to a Journal Article:

  1. Byron PR, Peart J, Staniforth JN (2018). Aerosol electrostatics. Properties of fine powders before and after aerosolisation by dry powder inhalers. Pharm. Res. 19: 698-705.
  2. Adagana FA and Gimba HE (2017). Urinary Tract infection in Pregnancy in a Nigerian Rural Setting. West Afr. J. Pharmacol. Drug Res. 15: (1&2), 8-12.
  3. Freeze AO and Capon ACD (2020). The anticoagulant activity of some selected warfarin analogues. J. Pharm. Pharmacol. 59: 142 – 144.

Journal names should be abbreviated according to the style used in index medicus or the BIOSIS list of Serials.

References to books

Tracy WT and Webster Jr LT. Drugs Used in the Chemotherapy of Protozoal Infections (Malaria). In: The Pharmacological Basis of therapeutics, EDs. Hardman JG, Limbird LE, and Gilman AG (McGraw-Hill Med Publ. Div). 10th Edition Ch 40.

Peart J. Orban JC, McGlynn, P, Redmon MP, Sargeant CM, Bron PR (2018). MDI electrostatics Valve and formulation interactions that really make a difference. In: Dalby RN, Brion PR, Peart J. Farr SJ, editors. Cardiovascular Drug Delivery VIII. Raleigh, NC: Davis Horwood International pp233-240.

  1. Ethical Considerations
  • Principal author must carry along all contributing authors in consent. To this end, a consent note will be sent to the corresponding author after a successful peer review process. All authors must append their signatures on the consent note which must be returned to the Editor-in-Chief before an article could be published.
  • Manuscripts are accepted on the grounds that they have not been sent elsewhere for publication.
  • Ethical clearance from relevant and appropriate Ethics committee must be obtained for all human and animal experimentation studies.
  1. Editorial Policy

Opinions and statements expressed in any presentation in JPSPP are those of the authors or product advertisers and not necessarily those of the publishers or the editorial board. The Editor-in-Chief shall not be liable for any errors contained in such materials

Article-processing charges

All accepted articles by the Journal of Pharmaceutical Sciences and Pharmacy Practice (JPSPP) would be open access articles, freely available online, immediately upon publication.  Open access publication is accompanied with a range of publishing expenses including provision of online tools for editors and authors, article production and hosting, liaison with abstracting and indexing services, and customer services. For sustainability of its open access therefore, the journal request authors to pay a token as article –processing charge for each article accepted for publication as detailed below:

JPSPP charges:                                                                          

Nigerian authors – ₦ 30, 000.00

International authors – $100.00

*Kindly note that all payments are non-refundable